vegfr - file.medchemexpress.com
TRANSCRIPT
VEGFRVascular endothelial growth factor receptor
VEGFRs consist of three subtypes the fms-like tyrosine kinase Flt-1 (VEGFR1Flt-1) the kinase domain region also referred to asfetal liver kinase (VEGFR2KDRFlk-1) and Flt-4 (VEGFR3) Each receptor has seven immunoglobulinlike domains in the extracellulardomain a single transmembrane region and a consensus tyrosine kinase sequence interrupted by a kinase insert domain VEGFR1and 2 are expressed on vascular endothelial cells whereas VEGFR3 is expressed on lymphatic endothelial The VEGF familymembers VEGF-A -B -C -D -E and PlGF and the human immunodeficiency (HIV) Tat protein bind in specific patterns to threerelated receptor protein tyrosine kinases VEGFR1 2 and 3 and induce the formation of homo- and heteromeric receptorcomplexes Binding of VEGF to VEGFR causes dimerization and autophosphorylation of the receptor Intracellular proteins such asVEGFR-associated protein (VRAP) PLC and Sck that associate with specific tyrosine residues of VEGFR are phosphorylated uponreceptor activation Several signal transduction pathways are activated by the binding of VEGF to its receptor leading to increasedproliferation survival permeability and migration of cells
wwwMedChemExpresscom 1
VEGFR Inhibitors amp Antagonists
(Rac)-SAR131675Cat No HY-123050
(Rac)-SAR131675 is the racemate of SAR131675SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
(Z)-GuggulsteroneCat No HY-110066
Z-guggulsterone a constituent of Indian Ayurvedicmedicinal plant inhibitsCommiphora mukulthe growth of human prostate cancer cells bycausing Z-guggulsterone inhibitsapoptosisangiogenesis by suppressing the VEGFndashVEGF-R2ndashAktsignaling axis
Purity 9827Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg
(Z)-Orantinib ((Z)-SU6668 (Z)-TSU-68) Cat No HY-10517A
(Z)-Orantinib ((Z)-SU6668) is a potent selectiveorally active and ATP competitive inhibitor of
and with s of 21Flk1KDR PDGFRβ FGFR1 IC50
0008 and 12 microM respectively (Z)-Orantinib isa potent antiangiogenic and antitumor agent thatinduces regression of established tumors
Purity 9902Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
3-Methylthienyl-carbonyl-JNJ-7706621Cat No HY-141685
3-Methylthienyl-carbonyl-JNJ-7706621 is a potentand selective inhibitor of cyclin-dependent kinase
with s of 64 nM and 2 nM for(CDK) IC50
and respectivelyCDK1cyclinB CDK2cyclinA
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
5Z-7-Oxozeaenol (FR148083 L783279 LL-Z 1640-2) Cat No HY-12686
5Z-7-Oxozeaenol is a natural anti-protozoancompound from fungal origin acting as a potentirreversible and selective inhibitor of andTAK1
with s of 8 nM and 52 nMVEGF-R2 IC50
respectively
Purity ge990Clinical Data No Development ReportedSize 1 mg
5α-Hydroxycostic acidCat No HY-N2666
5α-Hydroxycostic acid a eudesmane-typesesquiterpene is isolated from the herb Laggeraalata 5α-Hydroxycostic acid inhibits angiogenesisand suppresses breast cancer cell migrationthrough regulating and VEGFVEGFR2 Ang2Tie2pathways
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Acrizanib (LHA510) Cat No HY-109020
Acrizanib (LHA510) is a inhibitor withVEGFR-2an of 174 nM for BaF3-VEGFR-2IC50
Purity 9984Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
AG-13958 (AG-013958) Cat No HY-15492
AG-13958 (AG-013958) a potent VEGFR tyrosine inhibitor is used for treatment ofkinase
choroidal neovascularization associated withage-related macular degeneration (AMD)
Purity 9964Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
AhR modulator-1Cat No HY-135671
AhR modulator-1 (compound 6-MCDF) is a selectiveand orally active aryl hydrocarbon receptor (AhR)modulator AhR modulator-1 inhibits metastasis inpart by inhibiting productionprostatic VEGFprior to tumor formation AhR modulator-1 alsopossess anti- properties in rat uterusestrogenic
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Altiratinib (DCC-2701) Cat No HY-B0791
Altiratinib (DCC-2701) is a multi-targeted kinaseinhibitor with s of 27 8 92 93 085IC50
46 083 nM for MET TIE2 VEGFR2 FLT3 and respectivelyTrk1 Trk2 Trk3
Purity 9806Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
2 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
AMG-47aCat No HY-18303
AMG-47a is a potent and orally activelymphocyte-specific protein tyrosine kinase
inhibitor with an of 02 nM AMG-47a(Lck) IC50
also inhibits and andVEGF2 p38α Jak3 MLR with s of 1 nM 3 nM 72 nM 30 nM and 21IL-2 IC50
nM respectively
Purity 9871Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
AMG-Tie2-1Cat No HY-13023
AMG-Tie2-1 is an inhibitor of tunica interna with an of 1endothelial cell kinase 2 (Tie2) IC50
nM AMG-Tie2-1 is a VEGFR2 inhibitor with an IC50
of 3 nM
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
AST 487 (NVP-AST 487) Cat No HY-15002
AST 487 is a kinase inhibitor with ofRET IC50
880 nM inhibits RET autophosphorylation andactivation of downstream effectors also inhibits
with of 520 nMFlt-3 IC50
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
Axitinib (AG-013736) Cat No HY-10065
Axitinib is a multi-targeted tyrosine kinaseinhibitor with s of 01 02 01-03 16 nMIC50
for and VEGFR1 VEGFR2 VEGFR3 PDGFRβrespectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 50 mg 100 mg 200 mg 500 mg
Axitinib-d3 (AG-013736-d3) Cat No HY-10065S1
Axitinib-d3 (AG-013736-d3) is deuterium labeledAxitinib Axitinib is a multi-targeted tyrosinekinase inhibitor with s of 01 02 01-03IC50
16 nM for and VEGFR1 VEGFR2 VEGFR3 respectivelyPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
AZD2932Cat No HY-18179
AZD2932 is a potent and multi-targeted kinaseinhibitor and withVEGFR2 PDGFβ Flt-3 c-Kit
s of 8 4 7 and 9 nM in cell assayIC50
respectively
Purity 9611Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Bevacizumab (Anti-Human VEGF Humanized Antibody) Cat No HY-P9906
Bevacizumab a humanized monoclonal antibodyspecifically binds to all isoforms withVEGF-Ahigh affinity
Purity 9850Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
BFH772Cat No HY-100419
BFH772 is a potent oral inhibitor whichVEGFR2is highly effective at targeting VEGFR2 kinasewith an value of 3 nMIC50
Purity 9638Clinical Data Phase 2Size 5 mg 10 mg 25 mg 50 mg 100 mg
BIBF 1202Cat No HY-15992
BIBF 1202 is the carboxylate metabolite of BIBF1120 which inhibits kinase with an ofVEGFR2 IC50
62 nM
Purity 9929Clinical Data No Development ReportedSize 1 mg 5 mg
BMS-690514Cat No HY-10333
BMS-690514 is a potent and orally active inhibitorof and has s of 5 20 and 60 nMEGFR VEGFR IC50
for EGFR HER 2 and HER 4 respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
wwwMedChemExpresscom 3
BMS-794833Cat No HY-10497
BMS-794833 is a and inhibitorVEGFR2 Metextracted from patent WO2009094417 compoundexample 1 has s of 15 and 17 nMIC50
respectively
Purity 9978Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (BMS-540215) Cat No HY-10337
Brivanib (BMS-540215) is an ATP-competitiveinhibitor against with an of 25 nMVEGFR2 IC50
and has moderate potency against VEGFR-1 andFGFR-1 but gt240-fold against PDGFR-β
Purity 9937Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (alaninate) (BMS-582664) Cat No HY-10336
Brivanib alaninate (BMS-582664) is anATP-competitive inhibitor against with anVEGFR2
of 25 nM has moderate potency againstIC50
VEGFR-1 and FGFR-1 but more than 240-fold againstPDGFRβ
Purity 9945Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Cabozantinib (XL184 BMS-907351) Cat No HY-13016
Cabozantinib is a potent multiple receptortyrosine kinases (RTKs) inhibitor that inhibits
and with s ofVEGFR2 c-Met Kit Axl Flt3 IC50
0035 13 46 7 and 113 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib S-malate (XL184 S-malate BMS-907351 S-malate) Cat No HY-12044
Cabozantinib S-malate (XL184 S-malate) is a potentmultiple receptor tyrosine kinases inhibitor thatinhibits and withVEGFR2 c-Met Kit Axl Flt3
s of 0035 13 46 7 and 113 nMIC50
respectively
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib-d6Cat No HY-13016S
Cabozantinib-d6 (XL184-d6) is the deuteriumlabeled Cabozantinib Cabozantinib is a potentmultiple receptor tyrosine kinases (RTKs)inhibitor that inhibits VEGFR2 c-Met Kit Axland with s of 0035 13 46 7 and 113Flt3 IC50
nM respectively
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Cediranib (AZD2171) Cat No HY-10205
Cediranib (AZD2171) is a highly potent orallyavailable tyrosine kinase inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9958Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cediranib maleate (AZD-2171 maleate) Cat No HY-13049
Cediranib maleate (AZD-2171 maleate) is a highlypotent orally available inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9974Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Chiauranib (CS2164) Cat No HY-124526
Chiauranib (CS2164) is an orally activemulti-target inhibitor against tumor angiogenesis
Purity 9928Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Chloropyramine hydrochlorideCat No HY-B1305
Chloropyramine hydrochloride is a histamine antagonist which can also inhibit thereceptor H1
biochemical function of and VEGFR-3 FAK
Purity 9973Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg
4 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
CP-547632Cat No HY-13302
CP-547632 is an orally active ATP-competitive andpotent and kinases inhibitor withVEGFR-2 FGF
s of 11 nM and 9 nM respectively CP-547632IC50
is selective for VEGFR2 and bFGF over EGFRPDGFRβ and related tyrosine kinases (TKs)CP-547632 has antitumor efficacy
Purity 9871Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 hydrochlorideCat No HY-13302B
CP-547632 hydrochloride is an orally activeATP-competitive and potent and VEGFR-2 FGFkinases inhibitor with s of 11 nM and 9 nMIC50
respectively CP-547632 hydrochloride is selectivefor VEGFR2 and bFGF over EGFR PDGFRβ and relatedtyrosine kinases (TKs)
Purity 9824Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 TFACat No HY-13302C
CP-547632 TFA is an orally active ATP-competitiveand potent and kinases inhibitorVEGFR-2 FGFwith s of 11 nM and 9 nM respectivelyIC50
CP-547632 TFA is selective for VEGFR2 and bFGFover EGFR PDGFRβ and related tyrosine kinases(TKs) CP-547632 TFA has antitumor efficacy
Purity 9942Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Dovitinib (CHIR-258 TKI258) Cat No HY-50905
Dovitinib (CHIR-258) is a multi-targeted tyrosinekinase inhibitor with s of 1 2 89 10138IC50
27210 nM for FLT3 c-Kit FGFR1FGFR3 and VEGFR1VEGFR2VEGFR3 PDGFRαPDGFRβ
respectively
Purity 9994Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Dovitinib lactate (CHIR-258 lactate TKI-258 lactate) Cat No HY-10207
Dovitinib lactate (TKI258 lactate) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity 9996Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Dovitinib lactate hydrate (TKI258 lactate hydrate CHIR-258 lactate hydrate) Cat No HY-B0062
Dovitinib lactate hydrate (TKI258 lactate hydrate)is a multi-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Dovitinib-D8Cat No HY-50905S
Dovitinib-D8 (CHIR-258-D8) is the deuteriumlabeled Dovitinib Dovitinib (CHIR-258) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 andc-Kit FGFR1FGFR3 VEGFR1VEGFR2VEGFR3
respectivelyPDGFRαPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ENMD-2076Cat No HY-10987A
ENMD-2076 is a multi-targeted kinase inhibitorwith s of 186 14 582 159 927 708IC50
564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src PDGFRα
respectively
Purity 9912Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ENMD-2076 TartrateCat No HY-10987
ENMD-2076 Tartrate is a multi-targeted kinaseinhibitor with s of 186 14 582 159IC50
927 708 564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src
respectivelyPDGFRα
Purity 9887Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg
EOC317 (ACTB-1003) Cat No HY-16025
EOC317 (ACTB-1003) is an oral kinase inhibitorwith s of 6 2 and 4 nM for IC50 FGFR1 VEGFR2and Tie-2
Purity 9811Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 5
Foretinib (XL880 GSK1363089 GSK089 EXEL-2880) Cat No HY-10338
Foretinib is a multi-target tyrosine kinaseinhibitor with s of 04 nM and 09 nM forIC50
and Met KDR
Purity 9959Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Fruquintinib (HMPL-013) Cat No HY-19912
Fruquintinib (HMPL-013) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
33 035 and 35 nM respectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Gandotinib (LY2784544) Cat No HY-13034
Gandotinib (LY2784544) is a potent inhibitorJAK2with of 3 nM Gandotinib (LY2784544) alsoIC50
inhibits FLT3 FLT4 FGFR2 TYK2 and TRKB withIC of 4 25 32 44 and 95 nM50
Purity 9982Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Golvatinib (E-7050) Cat No HY-13068
Golvatinib (E-7050) is a potent dual inhibitor ofboth and kinases with s of 14c-Met VEGFR2 IC50
and 16 nM respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
GW768505A free baseCat No HY-125741
GW768505A free base is a potent dual inhibitor of and with a p of 781 forVEGFR2 (KDR) Tie-2 IC50
VEGFR2 GW768505A free base has anti-angiogenicactivity
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
GW806742XCat No HY-112292
GW806742X an ATP mimetic and a potent MLKL(Mixed Lineage Kinase Domain-Like protein)inhibitor binds the MLKL pseudokinase domain witha of 93 μM GW806742X has activity againstKd
( =2 nM) GW806742X retards MLKLVEGFR2 IC50
membrane translocation and inhibits necroptosis
Purity 9991Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
GW806742X hydrochlorideCat No HY-112292A
GW806742X hydrochloride an ATP mimetic and apotent MLKL (Mixed Lineage Kinase Domain-Like
inhibitor binds the MLKL pseudokinaseprotein)domain with a of 93 μM GW806742XKd
hydrochloride has activity against ( =2VEGFR2 IC50
nM)
Purity 9877Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
hVEGF-IN-1Cat No HY-101931
hVEGF-IN-1 a quinazoline derivative couldspecifically bind to the G-rich sequence in theinternal ribosome entry site A (IRES-A) anddestabilize the G-quadruplex structure hVEGF-IN-1binds to the IRES-A (WT) with a of 0928 μMKd
in SPR experiments
Purity 9831Clinical Data No Development ReportedSize 1 mg 5 mg 10 mg
HypothemycinCat No HY-107417
Hypothemycin a fungal polyketide is amultikinase inhibitor with s of 1070 nM 1738Ki
nM 90 nM 900 nM15 μM and 8424 μM for VEGFR2VEGFR1 MEK1MEK2 FLT-3 and respectivelyPDGFRβPDGFRα ERK1ERK2
Purity ge980Clinical Data No Development ReportedSize 1 mg
Ilorasertib (ABT-348) Cat No HY-16018
Ilorasertib (ABT-348) is a potent andATP-competitive multitargeted kinase inhibitorwhich inhibits and Aurora C Aurora B Aurora
with s of 1 nM 7 nM 120 nM respectivelyA IC50
Purity ge980Clinical Data Phase 2Size 50 mg 100 mg
6 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A
Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50
respectively
Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
JI-101Cat No HY-16265
JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity
Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
JNJ-38158471Cat No HY-18317
JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50
and with s of 180 and 500 nMRet Kit IC50
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
K00546Cat No HY-103647
K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B
respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50
respectively
Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Ki20227Cat No HY-10408
Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)
s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50
(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit
(platelet-derived growth factorhellipPDGFRβ
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
Ki8751Cat No HY-12038
Ki8751 is a potent inhibitor with an VEGFR2 IC50
of 09 nM
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
KRN-633Cat No HY-12060
KRN-633 is a potent inhibitor with s ofVEGFR IC50
170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively
Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib (E7080) Cat No HY-10981
Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3
and shows potentFGFR1-4 PDGFR KIT RETantitumor activities
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A
Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT
shows potent antitumor activitiesRET
Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Linifanib (ABT-869 AL-39324) Cat No HY-50751
Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50
PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity
Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 7
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR Inhibitors amp Antagonists
(Rac)-SAR131675Cat No HY-123050
(Rac)-SAR131675 is the racemate of SAR131675SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
(Z)-GuggulsteroneCat No HY-110066
Z-guggulsterone a constituent of Indian Ayurvedicmedicinal plant inhibitsCommiphora mukulthe growth of human prostate cancer cells bycausing Z-guggulsterone inhibitsapoptosisangiogenesis by suppressing the VEGFndashVEGF-R2ndashAktsignaling axis
Purity 9827Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg
(Z)-Orantinib ((Z)-SU6668 (Z)-TSU-68) Cat No HY-10517A
(Z)-Orantinib ((Z)-SU6668) is a potent selectiveorally active and ATP competitive inhibitor of
and with s of 21Flk1KDR PDGFRβ FGFR1 IC50
0008 and 12 microM respectively (Z)-Orantinib isa potent antiangiogenic and antitumor agent thatinduces regression of established tumors
Purity 9902Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
3-Methylthienyl-carbonyl-JNJ-7706621Cat No HY-141685
3-Methylthienyl-carbonyl-JNJ-7706621 is a potentand selective inhibitor of cyclin-dependent kinase
with s of 64 nM and 2 nM for(CDK) IC50
and respectivelyCDK1cyclinB CDK2cyclinA
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
5Z-7-Oxozeaenol (FR148083 L783279 LL-Z 1640-2) Cat No HY-12686
5Z-7-Oxozeaenol is a natural anti-protozoancompound from fungal origin acting as a potentirreversible and selective inhibitor of andTAK1
with s of 8 nM and 52 nMVEGF-R2 IC50
respectively
Purity ge990Clinical Data No Development ReportedSize 1 mg
5α-Hydroxycostic acidCat No HY-N2666
5α-Hydroxycostic acid a eudesmane-typesesquiterpene is isolated from the herb Laggeraalata 5α-Hydroxycostic acid inhibits angiogenesisand suppresses breast cancer cell migrationthrough regulating and VEGFVEGFR2 Ang2Tie2pathways
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Acrizanib (LHA510) Cat No HY-109020
Acrizanib (LHA510) is a inhibitor withVEGFR-2an of 174 nM for BaF3-VEGFR-2IC50
Purity 9984Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
AG-13958 (AG-013958) Cat No HY-15492
AG-13958 (AG-013958) a potent VEGFR tyrosine inhibitor is used for treatment ofkinase
choroidal neovascularization associated withage-related macular degeneration (AMD)
Purity 9964Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
AhR modulator-1Cat No HY-135671
AhR modulator-1 (compound 6-MCDF) is a selectiveand orally active aryl hydrocarbon receptor (AhR)modulator AhR modulator-1 inhibits metastasis inpart by inhibiting productionprostatic VEGFprior to tumor formation AhR modulator-1 alsopossess anti- properties in rat uterusestrogenic
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Altiratinib (DCC-2701) Cat No HY-B0791
Altiratinib (DCC-2701) is a multi-targeted kinaseinhibitor with s of 27 8 92 93 085IC50
46 083 nM for MET TIE2 VEGFR2 FLT3 and respectivelyTrk1 Trk2 Trk3
Purity 9806Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
2 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
AMG-47aCat No HY-18303
AMG-47a is a potent and orally activelymphocyte-specific protein tyrosine kinase
inhibitor with an of 02 nM AMG-47a(Lck) IC50
also inhibits and andVEGF2 p38α Jak3 MLR with s of 1 nM 3 nM 72 nM 30 nM and 21IL-2 IC50
nM respectively
Purity 9871Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
AMG-Tie2-1Cat No HY-13023
AMG-Tie2-1 is an inhibitor of tunica interna with an of 1endothelial cell kinase 2 (Tie2) IC50
nM AMG-Tie2-1 is a VEGFR2 inhibitor with an IC50
of 3 nM
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
AST 487 (NVP-AST 487) Cat No HY-15002
AST 487 is a kinase inhibitor with ofRET IC50
880 nM inhibits RET autophosphorylation andactivation of downstream effectors also inhibits
with of 520 nMFlt-3 IC50
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
Axitinib (AG-013736) Cat No HY-10065
Axitinib is a multi-targeted tyrosine kinaseinhibitor with s of 01 02 01-03 16 nMIC50
for and VEGFR1 VEGFR2 VEGFR3 PDGFRβrespectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 50 mg 100 mg 200 mg 500 mg
Axitinib-d3 (AG-013736-d3) Cat No HY-10065S1
Axitinib-d3 (AG-013736-d3) is deuterium labeledAxitinib Axitinib is a multi-targeted tyrosinekinase inhibitor with s of 01 02 01-03IC50
16 nM for and VEGFR1 VEGFR2 VEGFR3 respectivelyPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
AZD2932Cat No HY-18179
AZD2932 is a potent and multi-targeted kinaseinhibitor and withVEGFR2 PDGFβ Flt-3 c-Kit
s of 8 4 7 and 9 nM in cell assayIC50
respectively
Purity 9611Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Bevacizumab (Anti-Human VEGF Humanized Antibody) Cat No HY-P9906
Bevacizumab a humanized monoclonal antibodyspecifically binds to all isoforms withVEGF-Ahigh affinity
Purity 9850Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
BFH772Cat No HY-100419
BFH772 is a potent oral inhibitor whichVEGFR2is highly effective at targeting VEGFR2 kinasewith an value of 3 nMIC50
Purity 9638Clinical Data Phase 2Size 5 mg 10 mg 25 mg 50 mg 100 mg
BIBF 1202Cat No HY-15992
BIBF 1202 is the carboxylate metabolite of BIBF1120 which inhibits kinase with an ofVEGFR2 IC50
62 nM
Purity 9929Clinical Data No Development ReportedSize 1 mg 5 mg
BMS-690514Cat No HY-10333
BMS-690514 is a potent and orally active inhibitorof and has s of 5 20 and 60 nMEGFR VEGFR IC50
for EGFR HER 2 and HER 4 respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
wwwMedChemExpresscom 3
BMS-794833Cat No HY-10497
BMS-794833 is a and inhibitorVEGFR2 Metextracted from patent WO2009094417 compoundexample 1 has s of 15 and 17 nMIC50
respectively
Purity 9978Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (BMS-540215) Cat No HY-10337
Brivanib (BMS-540215) is an ATP-competitiveinhibitor against with an of 25 nMVEGFR2 IC50
and has moderate potency against VEGFR-1 andFGFR-1 but gt240-fold against PDGFR-β
Purity 9937Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (alaninate) (BMS-582664) Cat No HY-10336
Brivanib alaninate (BMS-582664) is anATP-competitive inhibitor against with anVEGFR2
of 25 nM has moderate potency againstIC50
VEGFR-1 and FGFR-1 but more than 240-fold againstPDGFRβ
Purity 9945Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Cabozantinib (XL184 BMS-907351) Cat No HY-13016
Cabozantinib is a potent multiple receptortyrosine kinases (RTKs) inhibitor that inhibits
and with s ofVEGFR2 c-Met Kit Axl Flt3 IC50
0035 13 46 7 and 113 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib S-malate (XL184 S-malate BMS-907351 S-malate) Cat No HY-12044
Cabozantinib S-malate (XL184 S-malate) is a potentmultiple receptor tyrosine kinases inhibitor thatinhibits and withVEGFR2 c-Met Kit Axl Flt3
s of 0035 13 46 7 and 113 nMIC50
respectively
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib-d6Cat No HY-13016S
Cabozantinib-d6 (XL184-d6) is the deuteriumlabeled Cabozantinib Cabozantinib is a potentmultiple receptor tyrosine kinases (RTKs)inhibitor that inhibits VEGFR2 c-Met Kit Axland with s of 0035 13 46 7 and 113Flt3 IC50
nM respectively
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Cediranib (AZD2171) Cat No HY-10205
Cediranib (AZD2171) is a highly potent orallyavailable tyrosine kinase inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9958Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cediranib maleate (AZD-2171 maleate) Cat No HY-13049
Cediranib maleate (AZD-2171 maleate) is a highlypotent orally available inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9974Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Chiauranib (CS2164) Cat No HY-124526
Chiauranib (CS2164) is an orally activemulti-target inhibitor against tumor angiogenesis
Purity 9928Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Chloropyramine hydrochlorideCat No HY-B1305
Chloropyramine hydrochloride is a histamine antagonist which can also inhibit thereceptor H1
biochemical function of and VEGFR-3 FAK
Purity 9973Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg
4 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
CP-547632Cat No HY-13302
CP-547632 is an orally active ATP-competitive andpotent and kinases inhibitor withVEGFR-2 FGF
s of 11 nM and 9 nM respectively CP-547632IC50
is selective for VEGFR2 and bFGF over EGFRPDGFRβ and related tyrosine kinases (TKs)CP-547632 has antitumor efficacy
Purity 9871Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 hydrochlorideCat No HY-13302B
CP-547632 hydrochloride is an orally activeATP-competitive and potent and VEGFR-2 FGFkinases inhibitor with s of 11 nM and 9 nMIC50
respectively CP-547632 hydrochloride is selectivefor VEGFR2 and bFGF over EGFR PDGFRβ and relatedtyrosine kinases (TKs)
Purity 9824Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 TFACat No HY-13302C
CP-547632 TFA is an orally active ATP-competitiveand potent and kinases inhibitorVEGFR-2 FGFwith s of 11 nM and 9 nM respectivelyIC50
CP-547632 TFA is selective for VEGFR2 and bFGFover EGFR PDGFRβ and related tyrosine kinases(TKs) CP-547632 TFA has antitumor efficacy
Purity 9942Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Dovitinib (CHIR-258 TKI258) Cat No HY-50905
Dovitinib (CHIR-258) is a multi-targeted tyrosinekinase inhibitor with s of 1 2 89 10138IC50
27210 nM for FLT3 c-Kit FGFR1FGFR3 and VEGFR1VEGFR2VEGFR3 PDGFRαPDGFRβ
respectively
Purity 9994Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Dovitinib lactate (CHIR-258 lactate TKI-258 lactate) Cat No HY-10207
Dovitinib lactate (TKI258 lactate) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity 9996Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Dovitinib lactate hydrate (TKI258 lactate hydrate CHIR-258 lactate hydrate) Cat No HY-B0062
Dovitinib lactate hydrate (TKI258 lactate hydrate)is a multi-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Dovitinib-D8Cat No HY-50905S
Dovitinib-D8 (CHIR-258-D8) is the deuteriumlabeled Dovitinib Dovitinib (CHIR-258) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 andc-Kit FGFR1FGFR3 VEGFR1VEGFR2VEGFR3
respectivelyPDGFRαPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ENMD-2076Cat No HY-10987A
ENMD-2076 is a multi-targeted kinase inhibitorwith s of 186 14 582 159 927 708IC50
564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src PDGFRα
respectively
Purity 9912Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ENMD-2076 TartrateCat No HY-10987
ENMD-2076 Tartrate is a multi-targeted kinaseinhibitor with s of 186 14 582 159IC50
927 708 564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src
respectivelyPDGFRα
Purity 9887Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg
EOC317 (ACTB-1003) Cat No HY-16025
EOC317 (ACTB-1003) is an oral kinase inhibitorwith s of 6 2 and 4 nM for IC50 FGFR1 VEGFR2and Tie-2
Purity 9811Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 5
Foretinib (XL880 GSK1363089 GSK089 EXEL-2880) Cat No HY-10338
Foretinib is a multi-target tyrosine kinaseinhibitor with s of 04 nM and 09 nM forIC50
and Met KDR
Purity 9959Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Fruquintinib (HMPL-013) Cat No HY-19912
Fruquintinib (HMPL-013) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
33 035 and 35 nM respectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Gandotinib (LY2784544) Cat No HY-13034
Gandotinib (LY2784544) is a potent inhibitorJAK2with of 3 nM Gandotinib (LY2784544) alsoIC50
inhibits FLT3 FLT4 FGFR2 TYK2 and TRKB withIC of 4 25 32 44 and 95 nM50
Purity 9982Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Golvatinib (E-7050) Cat No HY-13068
Golvatinib (E-7050) is a potent dual inhibitor ofboth and kinases with s of 14c-Met VEGFR2 IC50
and 16 nM respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
GW768505A free baseCat No HY-125741
GW768505A free base is a potent dual inhibitor of and with a p of 781 forVEGFR2 (KDR) Tie-2 IC50
VEGFR2 GW768505A free base has anti-angiogenicactivity
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
GW806742XCat No HY-112292
GW806742X an ATP mimetic and a potent MLKL(Mixed Lineage Kinase Domain-Like protein)inhibitor binds the MLKL pseudokinase domain witha of 93 μM GW806742X has activity againstKd
( =2 nM) GW806742X retards MLKLVEGFR2 IC50
membrane translocation and inhibits necroptosis
Purity 9991Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
GW806742X hydrochlorideCat No HY-112292A
GW806742X hydrochloride an ATP mimetic and apotent MLKL (Mixed Lineage Kinase Domain-Like
inhibitor binds the MLKL pseudokinaseprotein)domain with a of 93 μM GW806742XKd
hydrochloride has activity against ( =2VEGFR2 IC50
nM)
Purity 9877Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
hVEGF-IN-1Cat No HY-101931
hVEGF-IN-1 a quinazoline derivative couldspecifically bind to the G-rich sequence in theinternal ribosome entry site A (IRES-A) anddestabilize the G-quadruplex structure hVEGF-IN-1binds to the IRES-A (WT) with a of 0928 μMKd
in SPR experiments
Purity 9831Clinical Data No Development ReportedSize 1 mg 5 mg 10 mg
HypothemycinCat No HY-107417
Hypothemycin a fungal polyketide is amultikinase inhibitor with s of 1070 nM 1738Ki
nM 90 nM 900 nM15 μM and 8424 μM for VEGFR2VEGFR1 MEK1MEK2 FLT-3 and respectivelyPDGFRβPDGFRα ERK1ERK2
Purity ge980Clinical Data No Development ReportedSize 1 mg
Ilorasertib (ABT-348) Cat No HY-16018
Ilorasertib (ABT-348) is a potent andATP-competitive multitargeted kinase inhibitorwhich inhibits and Aurora C Aurora B Aurora
with s of 1 nM 7 nM 120 nM respectivelyA IC50
Purity ge980Clinical Data Phase 2Size 50 mg 100 mg
6 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A
Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50
respectively
Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
JI-101Cat No HY-16265
JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity
Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
JNJ-38158471Cat No HY-18317
JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50
and with s of 180 and 500 nMRet Kit IC50
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
K00546Cat No HY-103647
K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B
respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50
respectively
Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Ki20227Cat No HY-10408
Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)
s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50
(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit
(platelet-derived growth factorhellipPDGFRβ
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
Ki8751Cat No HY-12038
Ki8751 is a potent inhibitor with an VEGFR2 IC50
of 09 nM
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
KRN-633Cat No HY-12060
KRN-633 is a potent inhibitor with s ofVEGFR IC50
170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively
Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib (E7080) Cat No HY-10981
Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3
and shows potentFGFR1-4 PDGFR KIT RETantitumor activities
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A
Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT
shows potent antitumor activitiesRET
Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Linifanib (ABT-869 AL-39324) Cat No HY-50751
Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50
PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity
Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 7
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
AMG-47aCat No HY-18303
AMG-47a is a potent and orally activelymphocyte-specific protein tyrosine kinase
inhibitor with an of 02 nM AMG-47a(Lck) IC50
also inhibits and andVEGF2 p38α Jak3 MLR with s of 1 nM 3 nM 72 nM 30 nM and 21IL-2 IC50
nM respectively
Purity 9871Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
AMG-Tie2-1Cat No HY-13023
AMG-Tie2-1 is an inhibitor of tunica interna with an of 1endothelial cell kinase 2 (Tie2) IC50
nM AMG-Tie2-1 is a VEGFR2 inhibitor with an IC50
of 3 nM
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
AST 487 (NVP-AST 487) Cat No HY-15002
AST 487 is a kinase inhibitor with ofRET IC50
880 nM inhibits RET autophosphorylation andactivation of downstream effectors also inhibits
with of 520 nMFlt-3 IC50
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
Axitinib (AG-013736) Cat No HY-10065
Axitinib is a multi-targeted tyrosine kinaseinhibitor with s of 01 02 01-03 16 nMIC50
for and VEGFR1 VEGFR2 VEGFR3 PDGFRβrespectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 50 mg 100 mg 200 mg 500 mg
Axitinib-d3 (AG-013736-d3) Cat No HY-10065S1
Axitinib-d3 (AG-013736-d3) is deuterium labeledAxitinib Axitinib is a multi-targeted tyrosinekinase inhibitor with s of 01 02 01-03IC50
16 nM for and VEGFR1 VEGFR2 VEGFR3 respectivelyPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
AZD2932Cat No HY-18179
AZD2932 is a potent and multi-targeted kinaseinhibitor and withVEGFR2 PDGFβ Flt-3 c-Kit
s of 8 4 7 and 9 nM in cell assayIC50
respectively
Purity 9611Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Bevacizumab (Anti-Human VEGF Humanized Antibody) Cat No HY-P9906
Bevacizumab a humanized monoclonal antibodyspecifically binds to all isoforms withVEGF-Ahigh affinity
Purity 9850Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
BFH772Cat No HY-100419
BFH772 is a potent oral inhibitor whichVEGFR2is highly effective at targeting VEGFR2 kinasewith an value of 3 nMIC50
Purity 9638Clinical Data Phase 2Size 5 mg 10 mg 25 mg 50 mg 100 mg
BIBF 1202Cat No HY-15992
BIBF 1202 is the carboxylate metabolite of BIBF1120 which inhibits kinase with an ofVEGFR2 IC50
62 nM
Purity 9929Clinical Data No Development ReportedSize 1 mg 5 mg
BMS-690514Cat No HY-10333
BMS-690514 is a potent and orally active inhibitorof and has s of 5 20 and 60 nMEGFR VEGFR IC50
for EGFR HER 2 and HER 4 respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
wwwMedChemExpresscom 3
BMS-794833Cat No HY-10497
BMS-794833 is a and inhibitorVEGFR2 Metextracted from patent WO2009094417 compoundexample 1 has s of 15 and 17 nMIC50
respectively
Purity 9978Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (BMS-540215) Cat No HY-10337
Brivanib (BMS-540215) is an ATP-competitiveinhibitor against with an of 25 nMVEGFR2 IC50
and has moderate potency against VEGFR-1 andFGFR-1 but gt240-fold against PDGFR-β
Purity 9937Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (alaninate) (BMS-582664) Cat No HY-10336
Brivanib alaninate (BMS-582664) is anATP-competitive inhibitor against with anVEGFR2
of 25 nM has moderate potency againstIC50
VEGFR-1 and FGFR-1 but more than 240-fold againstPDGFRβ
Purity 9945Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Cabozantinib (XL184 BMS-907351) Cat No HY-13016
Cabozantinib is a potent multiple receptortyrosine kinases (RTKs) inhibitor that inhibits
and with s ofVEGFR2 c-Met Kit Axl Flt3 IC50
0035 13 46 7 and 113 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib S-malate (XL184 S-malate BMS-907351 S-malate) Cat No HY-12044
Cabozantinib S-malate (XL184 S-malate) is a potentmultiple receptor tyrosine kinases inhibitor thatinhibits and withVEGFR2 c-Met Kit Axl Flt3
s of 0035 13 46 7 and 113 nMIC50
respectively
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib-d6Cat No HY-13016S
Cabozantinib-d6 (XL184-d6) is the deuteriumlabeled Cabozantinib Cabozantinib is a potentmultiple receptor tyrosine kinases (RTKs)inhibitor that inhibits VEGFR2 c-Met Kit Axland with s of 0035 13 46 7 and 113Flt3 IC50
nM respectively
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Cediranib (AZD2171) Cat No HY-10205
Cediranib (AZD2171) is a highly potent orallyavailable tyrosine kinase inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9958Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cediranib maleate (AZD-2171 maleate) Cat No HY-13049
Cediranib maleate (AZD-2171 maleate) is a highlypotent orally available inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9974Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Chiauranib (CS2164) Cat No HY-124526
Chiauranib (CS2164) is an orally activemulti-target inhibitor against tumor angiogenesis
Purity 9928Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Chloropyramine hydrochlorideCat No HY-B1305
Chloropyramine hydrochloride is a histamine antagonist which can also inhibit thereceptor H1
biochemical function of and VEGFR-3 FAK
Purity 9973Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg
4 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
CP-547632Cat No HY-13302
CP-547632 is an orally active ATP-competitive andpotent and kinases inhibitor withVEGFR-2 FGF
s of 11 nM and 9 nM respectively CP-547632IC50
is selective for VEGFR2 and bFGF over EGFRPDGFRβ and related tyrosine kinases (TKs)CP-547632 has antitumor efficacy
Purity 9871Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 hydrochlorideCat No HY-13302B
CP-547632 hydrochloride is an orally activeATP-competitive and potent and VEGFR-2 FGFkinases inhibitor with s of 11 nM and 9 nMIC50
respectively CP-547632 hydrochloride is selectivefor VEGFR2 and bFGF over EGFR PDGFRβ and relatedtyrosine kinases (TKs)
Purity 9824Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 TFACat No HY-13302C
CP-547632 TFA is an orally active ATP-competitiveand potent and kinases inhibitorVEGFR-2 FGFwith s of 11 nM and 9 nM respectivelyIC50
CP-547632 TFA is selective for VEGFR2 and bFGFover EGFR PDGFRβ and related tyrosine kinases(TKs) CP-547632 TFA has antitumor efficacy
Purity 9942Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Dovitinib (CHIR-258 TKI258) Cat No HY-50905
Dovitinib (CHIR-258) is a multi-targeted tyrosinekinase inhibitor with s of 1 2 89 10138IC50
27210 nM for FLT3 c-Kit FGFR1FGFR3 and VEGFR1VEGFR2VEGFR3 PDGFRαPDGFRβ
respectively
Purity 9994Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Dovitinib lactate (CHIR-258 lactate TKI-258 lactate) Cat No HY-10207
Dovitinib lactate (TKI258 lactate) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity 9996Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Dovitinib lactate hydrate (TKI258 lactate hydrate CHIR-258 lactate hydrate) Cat No HY-B0062
Dovitinib lactate hydrate (TKI258 lactate hydrate)is a multi-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Dovitinib-D8Cat No HY-50905S
Dovitinib-D8 (CHIR-258-D8) is the deuteriumlabeled Dovitinib Dovitinib (CHIR-258) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 andc-Kit FGFR1FGFR3 VEGFR1VEGFR2VEGFR3
respectivelyPDGFRαPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ENMD-2076Cat No HY-10987A
ENMD-2076 is a multi-targeted kinase inhibitorwith s of 186 14 582 159 927 708IC50
564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src PDGFRα
respectively
Purity 9912Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ENMD-2076 TartrateCat No HY-10987
ENMD-2076 Tartrate is a multi-targeted kinaseinhibitor with s of 186 14 582 159IC50
927 708 564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src
respectivelyPDGFRα
Purity 9887Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg
EOC317 (ACTB-1003) Cat No HY-16025
EOC317 (ACTB-1003) is an oral kinase inhibitorwith s of 6 2 and 4 nM for IC50 FGFR1 VEGFR2and Tie-2
Purity 9811Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 5
Foretinib (XL880 GSK1363089 GSK089 EXEL-2880) Cat No HY-10338
Foretinib is a multi-target tyrosine kinaseinhibitor with s of 04 nM and 09 nM forIC50
and Met KDR
Purity 9959Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Fruquintinib (HMPL-013) Cat No HY-19912
Fruquintinib (HMPL-013) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
33 035 and 35 nM respectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Gandotinib (LY2784544) Cat No HY-13034
Gandotinib (LY2784544) is a potent inhibitorJAK2with of 3 nM Gandotinib (LY2784544) alsoIC50
inhibits FLT3 FLT4 FGFR2 TYK2 and TRKB withIC of 4 25 32 44 and 95 nM50
Purity 9982Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Golvatinib (E-7050) Cat No HY-13068
Golvatinib (E-7050) is a potent dual inhibitor ofboth and kinases with s of 14c-Met VEGFR2 IC50
and 16 nM respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
GW768505A free baseCat No HY-125741
GW768505A free base is a potent dual inhibitor of and with a p of 781 forVEGFR2 (KDR) Tie-2 IC50
VEGFR2 GW768505A free base has anti-angiogenicactivity
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
GW806742XCat No HY-112292
GW806742X an ATP mimetic and a potent MLKL(Mixed Lineage Kinase Domain-Like protein)inhibitor binds the MLKL pseudokinase domain witha of 93 μM GW806742X has activity againstKd
( =2 nM) GW806742X retards MLKLVEGFR2 IC50
membrane translocation and inhibits necroptosis
Purity 9991Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
GW806742X hydrochlorideCat No HY-112292A
GW806742X hydrochloride an ATP mimetic and apotent MLKL (Mixed Lineage Kinase Domain-Like
inhibitor binds the MLKL pseudokinaseprotein)domain with a of 93 μM GW806742XKd
hydrochloride has activity against ( =2VEGFR2 IC50
nM)
Purity 9877Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
hVEGF-IN-1Cat No HY-101931
hVEGF-IN-1 a quinazoline derivative couldspecifically bind to the G-rich sequence in theinternal ribosome entry site A (IRES-A) anddestabilize the G-quadruplex structure hVEGF-IN-1binds to the IRES-A (WT) with a of 0928 μMKd
in SPR experiments
Purity 9831Clinical Data No Development ReportedSize 1 mg 5 mg 10 mg
HypothemycinCat No HY-107417
Hypothemycin a fungal polyketide is amultikinase inhibitor with s of 1070 nM 1738Ki
nM 90 nM 900 nM15 μM and 8424 μM for VEGFR2VEGFR1 MEK1MEK2 FLT-3 and respectivelyPDGFRβPDGFRα ERK1ERK2
Purity ge980Clinical Data No Development ReportedSize 1 mg
Ilorasertib (ABT-348) Cat No HY-16018
Ilorasertib (ABT-348) is a potent andATP-competitive multitargeted kinase inhibitorwhich inhibits and Aurora C Aurora B Aurora
with s of 1 nM 7 nM 120 nM respectivelyA IC50
Purity ge980Clinical Data Phase 2Size 50 mg 100 mg
6 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A
Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50
respectively
Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
JI-101Cat No HY-16265
JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity
Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
JNJ-38158471Cat No HY-18317
JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50
and with s of 180 and 500 nMRet Kit IC50
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
K00546Cat No HY-103647
K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B
respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50
respectively
Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Ki20227Cat No HY-10408
Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)
s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50
(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit
(platelet-derived growth factorhellipPDGFRβ
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
Ki8751Cat No HY-12038
Ki8751 is a potent inhibitor with an VEGFR2 IC50
of 09 nM
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
KRN-633Cat No HY-12060
KRN-633 is a potent inhibitor with s ofVEGFR IC50
170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively
Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib (E7080) Cat No HY-10981
Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3
and shows potentFGFR1-4 PDGFR KIT RETantitumor activities
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A
Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT
shows potent antitumor activitiesRET
Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Linifanib (ABT-869 AL-39324) Cat No HY-50751
Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50
PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity
Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 7
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
BMS-794833Cat No HY-10497
BMS-794833 is a and inhibitorVEGFR2 Metextracted from patent WO2009094417 compoundexample 1 has s of 15 and 17 nMIC50
respectively
Purity 9978Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (BMS-540215) Cat No HY-10337
Brivanib (BMS-540215) is an ATP-competitiveinhibitor against with an of 25 nMVEGFR2 IC50
and has moderate potency against VEGFR-1 andFGFR-1 but gt240-fold against PDGFR-β
Purity 9937Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Brivanib (alaninate) (BMS-582664) Cat No HY-10336
Brivanib alaninate (BMS-582664) is anATP-competitive inhibitor against with anVEGFR2
of 25 nM has moderate potency againstIC50
VEGFR-1 and FGFR-1 but more than 240-fold againstPDGFRβ
Purity 9945Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Cabozantinib (XL184 BMS-907351) Cat No HY-13016
Cabozantinib is a potent multiple receptortyrosine kinases (RTKs) inhibitor that inhibits
and with s ofVEGFR2 c-Met Kit Axl Flt3 IC50
0035 13 46 7 and 113 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib S-malate (XL184 S-malate BMS-907351 S-malate) Cat No HY-12044
Cabozantinib S-malate (XL184 S-malate) is a potentmultiple receptor tyrosine kinases inhibitor thatinhibits and withVEGFR2 c-Met Kit Axl Flt3
s of 0035 13 46 7 and 113 nMIC50
respectively
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cabozantinib-d6Cat No HY-13016S
Cabozantinib-d6 (XL184-d6) is the deuteriumlabeled Cabozantinib Cabozantinib is a potentmultiple receptor tyrosine kinases (RTKs)inhibitor that inhibits VEGFR2 c-Met Kit Axland with s of 0035 13 46 7 and 113Flt3 IC50
nM respectively
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Cediranib (AZD2171) Cat No HY-10205
Cediranib (AZD2171) is a highly potent orallyavailable tyrosine kinase inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9958Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Cediranib maleate (AZD-2171 maleate) Cat No HY-13049
Cediranib maleate (AZD-2171 maleate) is a highlypotent orally available inhibitor withVEGFR
s of lt1 lt3 5 5 36 2 nM for Flt1IC50
KDR Flt4 PDGFRα PDGFRβ c-Kit respectively
Purity 9974Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Chiauranib (CS2164) Cat No HY-124526
Chiauranib (CS2164) is an orally activemulti-target inhibitor against tumor angiogenesis
Purity 9928Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Chloropyramine hydrochlorideCat No HY-B1305
Chloropyramine hydrochloride is a histamine antagonist which can also inhibit thereceptor H1
biochemical function of and VEGFR-3 FAK
Purity 9973Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg
4 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
CP-547632Cat No HY-13302
CP-547632 is an orally active ATP-competitive andpotent and kinases inhibitor withVEGFR-2 FGF
s of 11 nM and 9 nM respectively CP-547632IC50
is selective for VEGFR2 and bFGF over EGFRPDGFRβ and related tyrosine kinases (TKs)CP-547632 has antitumor efficacy
Purity 9871Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 hydrochlorideCat No HY-13302B
CP-547632 hydrochloride is an orally activeATP-competitive and potent and VEGFR-2 FGFkinases inhibitor with s of 11 nM and 9 nMIC50
respectively CP-547632 hydrochloride is selectivefor VEGFR2 and bFGF over EGFR PDGFRβ and relatedtyrosine kinases (TKs)
Purity 9824Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 TFACat No HY-13302C
CP-547632 TFA is an orally active ATP-competitiveand potent and kinases inhibitorVEGFR-2 FGFwith s of 11 nM and 9 nM respectivelyIC50
CP-547632 TFA is selective for VEGFR2 and bFGFover EGFR PDGFRβ and related tyrosine kinases(TKs) CP-547632 TFA has antitumor efficacy
Purity 9942Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Dovitinib (CHIR-258 TKI258) Cat No HY-50905
Dovitinib (CHIR-258) is a multi-targeted tyrosinekinase inhibitor with s of 1 2 89 10138IC50
27210 nM for FLT3 c-Kit FGFR1FGFR3 and VEGFR1VEGFR2VEGFR3 PDGFRαPDGFRβ
respectively
Purity 9994Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Dovitinib lactate (CHIR-258 lactate TKI-258 lactate) Cat No HY-10207
Dovitinib lactate (TKI258 lactate) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity 9996Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Dovitinib lactate hydrate (TKI258 lactate hydrate CHIR-258 lactate hydrate) Cat No HY-B0062
Dovitinib lactate hydrate (TKI258 lactate hydrate)is a multi-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Dovitinib-D8Cat No HY-50905S
Dovitinib-D8 (CHIR-258-D8) is the deuteriumlabeled Dovitinib Dovitinib (CHIR-258) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 andc-Kit FGFR1FGFR3 VEGFR1VEGFR2VEGFR3
respectivelyPDGFRαPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ENMD-2076Cat No HY-10987A
ENMD-2076 is a multi-targeted kinase inhibitorwith s of 186 14 582 159 927 708IC50
564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src PDGFRα
respectively
Purity 9912Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ENMD-2076 TartrateCat No HY-10987
ENMD-2076 Tartrate is a multi-targeted kinaseinhibitor with s of 186 14 582 159IC50
927 708 564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src
respectivelyPDGFRα
Purity 9887Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg
EOC317 (ACTB-1003) Cat No HY-16025
EOC317 (ACTB-1003) is an oral kinase inhibitorwith s of 6 2 and 4 nM for IC50 FGFR1 VEGFR2and Tie-2
Purity 9811Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 5
Foretinib (XL880 GSK1363089 GSK089 EXEL-2880) Cat No HY-10338
Foretinib is a multi-target tyrosine kinaseinhibitor with s of 04 nM and 09 nM forIC50
and Met KDR
Purity 9959Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Fruquintinib (HMPL-013) Cat No HY-19912
Fruquintinib (HMPL-013) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
33 035 and 35 nM respectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Gandotinib (LY2784544) Cat No HY-13034
Gandotinib (LY2784544) is a potent inhibitorJAK2with of 3 nM Gandotinib (LY2784544) alsoIC50
inhibits FLT3 FLT4 FGFR2 TYK2 and TRKB withIC of 4 25 32 44 and 95 nM50
Purity 9982Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Golvatinib (E-7050) Cat No HY-13068
Golvatinib (E-7050) is a potent dual inhibitor ofboth and kinases with s of 14c-Met VEGFR2 IC50
and 16 nM respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
GW768505A free baseCat No HY-125741
GW768505A free base is a potent dual inhibitor of and with a p of 781 forVEGFR2 (KDR) Tie-2 IC50
VEGFR2 GW768505A free base has anti-angiogenicactivity
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
GW806742XCat No HY-112292
GW806742X an ATP mimetic and a potent MLKL(Mixed Lineage Kinase Domain-Like protein)inhibitor binds the MLKL pseudokinase domain witha of 93 μM GW806742X has activity againstKd
( =2 nM) GW806742X retards MLKLVEGFR2 IC50
membrane translocation and inhibits necroptosis
Purity 9991Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
GW806742X hydrochlorideCat No HY-112292A
GW806742X hydrochloride an ATP mimetic and apotent MLKL (Mixed Lineage Kinase Domain-Like
inhibitor binds the MLKL pseudokinaseprotein)domain with a of 93 μM GW806742XKd
hydrochloride has activity against ( =2VEGFR2 IC50
nM)
Purity 9877Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
hVEGF-IN-1Cat No HY-101931
hVEGF-IN-1 a quinazoline derivative couldspecifically bind to the G-rich sequence in theinternal ribosome entry site A (IRES-A) anddestabilize the G-quadruplex structure hVEGF-IN-1binds to the IRES-A (WT) with a of 0928 μMKd
in SPR experiments
Purity 9831Clinical Data No Development ReportedSize 1 mg 5 mg 10 mg
HypothemycinCat No HY-107417
Hypothemycin a fungal polyketide is amultikinase inhibitor with s of 1070 nM 1738Ki
nM 90 nM 900 nM15 μM and 8424 μM for VEGFR2VEGFR1 MEK1MEK2 FLT-3 and respectivelyPDGFRβPDGFRα ERK1ERK2
Purity ge980Clinical Data No Development ReportedSize 1 mg
Ilorasertib (ABT-348) Cat No HY-16018
Ilorasertib (ABT-348) is a potent andATP-competitive multitargeted kinase inhibitorwhich inhibits and Aurora C Aurora B Aurora
with s of 1 nM 7 nM 120 nM respectivelyA IC50
Purity ge980Clinical Data Phase 2Size 50 mg 100 mg
6 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A
Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50
respectively
Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
JI-101Cat No HY-16265
JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity
Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
JNJ-38158471Cat No HY-18317
JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50
and with s of 180 and 500 nMRet Kit IC50
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
K00546Cat No HY-103647
K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B
respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50
respectively
Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Ki20227Cat No HY-10408
Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)
s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50
(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit
(platelet-derived growth factorhellipPDGFRβ
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
Ki8751Cat No HY-12038
Ki8751 is a potent inhibitor with an VEGFR2 IC50
of 09 nM
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
KRN-633Cat No HY-12060
KRN-633 is a potent inhibitor with s ofVEGFR IC50
170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively
Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib (E7080) Cat No HY-10981
Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3
and shows potentFGFR1-4 PDGFR KIT RETantitumor activities
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A
Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT
shows potent antitumor activitiesRET
Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Linifanib (ABT-869 AL-39324) Cat No HY-50751
Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50
PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity
Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 7
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
CP-547632Cat No HY-13302
CP-547632 is an orally active ATP-competitive andpotent and kinases inhibitor withVEGFR-2 FGF
s of 11 nM and 9 nM respectively CP-547632IC50
is selective for VEGFR2 and bFGF over EGFRPDGFRβ and related tyrosine kinases (TKs)CP-547632 has antitumor efficacy
Purity 9871Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 hydrochlorideCat No HY-13302B
CP-547632 hydrochloride is an orally activeATP-competitive and potent and VEGFR-2 FGFkinases inhibitor with s of 11 nM and 9 nMIC50
respectively CP-547632 hydrochloride is selectivefor VEGFR2 and bFGF over EGFR PDGFRβ and relatedtyrosine kinases (TKs)
Purity 9824Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
CP-547632 TFACat No HY-13302C
CP-547632 TFA is an orally active ATP-competitiveand potent and kinases inhibitorVEGFR-2 FGFwith s of 11 nM and 9 nM respectivelyIC50
CP-547632 TFA is selective for VEGFR2 and bFGFover EGFR PDGFRβ and related tyrosine kinases(TKs) CP-547632 TFA has antitumor efficacy
Purity 9942Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Dovitinib (CHIR-258 TKI258) Cat No HY-50905
Dovitinib (CHIR-258) is a multi-targeted tyrosinekinase inhibitor with s of 1 2 89 10138IC50
27210 nM for FLT3 c-Kit FGFR1FGFR3 and VEGFR1VEGFR2VEGFR3 PDGFRαPDGFRβ
respectively
Purity 9994Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Dovitinib lactate (CHIR-258 lactate TKI-258 lactate) Cat No HY-10207
Dovitinib lactate (TKI258 lactate) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity 9996Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Dovitinib lactate hydrate (TKI258 lactate hydrate CHIR-258 lactate hydrate) Cat No HY-B0062
Dovitinib lactate hydrate (TKI258 lactate hydrate)is a multi-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 and c-Kit FGFR13 VEGFR123 PDGFRαβ
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Dovitinib-D8Cat No HY-50905S
Dovitinib-D8 (CHIR-258-D8) is the deuteriumlabeled Dovitinib Dovitinib (CHIR-258) is amulti-targeted tyrosine kinase inhibitor with
s of 1 2 89 10138 27210 nM for IC50 FLT3 andc-Kit FGFR1FGFR3 VEGFR1VEGFR2VEGFR3
respectivelyPDGFRαPDGFRβ
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ENMD-2076Cat No HY-10987A
ENMD-2076 is a multi-targeted kinase inhibitorwith s of 186 14 582 159 927 708IC50
564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src PDGFRα
respectively
Purity 9912Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ENMD-2076 TartrateCat No HY-10987
ENMD-2076 Tartrate is a multi-targeted kinaseinhibitor with s of 186 14 582 159IC50
927 708 564 nM for Aurora A Flt3 KDRVEGFR2 Flt4VEGFR3 FGFR1 FGFR2 Src
respectivelyPDGFRα
Purity 9887Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg
EOC317 (ACTB-1003) Cat No HY-16025
EOC317 (ACTB-1003) is an oral kinase inhibitorwith s of 6 2 and 4 nM for IC50 FGFR1 VEGFR2and Tie-2
Purity 9811Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 5
Foretinib (XL880 GSK1363089 GSK089 EXEL-2880) Cat No HY-10338
Foretinib is a multi-target tyrosine kinaseinhibitor with s of 04 nM and 09 nM forIC50
and Met KDR
Purity 9959Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Fruquintinib (HMPL-013) Cat No HY-19912
Fruquintinib (HMPL-013) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
33 035 and 35 nM respectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Gandotinib (LY2784544) Cat No HY-13034
Gandotinib (LY2784544) is a potent inhibitorJAK2with of 3 nM Gandotinib (LY2784544) alsoIC50
inhibits FLT3 FLT4 FGFR2 TYK2 and TRKB withIC of 4 25 32 44 and 95 nM50
Purity 9982Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Golvatinib (E-7050) Cat No HY-13068
Golvatinib (E-7050) is a potent dual inhibitor ofboth and kinases with s of 14c-Met VEGFR2 IC50
and 16 nM respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
GW768505A free baseCat No HY-125741
GW768505A free base is a potent dual inhibitor of and with a p of 781 forVEGFR2 (KDR) Tie-2 IC50
VEGFR2 GW768505A free base has anti-angiogenicactivity
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
GW806742XCat No HY-112292
GW806742X an ATP mimetic and a potent MLKL(Mixed Lineage Kinase Domain-Like protein)inhibitor binds the MLKL pseudokinase domain witha of 93 μM GW806742X has activity againstKd
( =2 nM) GW806742X retards MLKLVEGFR2 IC50
membrane translocation and inhibits necroptosis
Purity 9991Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
GW806742X hydrochlorideCat No HY-112292A
GW806742X hydrochloride an ATP mimetic and apotent MLKL (Mixed Lineage Kinase Domain-Like
inhibitor binds the MLKL pseudokinaseprotein)domain with a of 93 μM GW806742XKd
hydrochloride has activity against ( =2VEGFR2 IC50
nM)
Purity 9877Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
hVEGF-IN-1Cat No HY-101931
hVEGF-IN-1 a quinazoline derivative couldspecifically bind to the G-rich sequence in theinternal ribosome entry site A (IRES-A) anddestabilize the G-quadruplex structure hVEGF-IN-1binds to the IRES-A (WT) with a of 0928 μMKd
in SPR experiments
Purity 9831Clinical Data No Development ReportedSize 1 mg 5 mg 10 mg
HypothemycinCat No HY-107417
Hypothemycin a fungal polyketide is amultikinase inhibitor with s of 1070 nM 1738Ki
nM 90 nM 900 nM15 μM and 8424 μM for VEGFR2VEGFR1 MEK1MEK2 FLT-3 and respectivelyPDGFRβPDGFRα ERK1ERK2
Purity ge980Clinical Data No Development ReportedSize 1 mg
Ilorasertib (ABT-348) Cat No HY-16018
Ilorasertib (ABT-348) is a potent andATP-competitive multitargeted kinase inhibitorwhich inhibits and Aurora C Aurora B Aurora
with s of 1 nM 7 nM 120 nM respectivelyA IC50
Purity ge980Clinical Data Phase 2Size 50 mg 100 mg
6 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A
Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50
respectively
Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
JI-101Cat No HY-16265
JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity
Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
JNJ-38158471Cat No HY-18317
JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50
and with s of 180 and 500 nMRet Kit IC50
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
K00546Cat No HY-103647
K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B
respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50
respectively
Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Ki20227Cat No HY-10408
Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)
s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50
(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit
(platelet-derived growth factorhellipPDGFRβ
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
Ki8751Cat No HY-12038
Ki8751 is a potent inhibitor with an VEGFR2 IC50
of 09 nM
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
KRN-633Cat No HY-12060
KRN-633 is a potent inhibitor with s ofVEGFR IC50
170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively
Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib (E7080) Cat No HY-10981
Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3
and shows potentFGFR1-4 PDGFR KIT RETantitumor activities
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A
Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT
shows potent antitumor activitiesRET
Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Linifanib (ABT-869 AL-39324) Cat No HY-50751
Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50
PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity
Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 7
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Foretinib (XL880 GSK1363089 GSK089 EXEL-2880) Cat No HY-10338
Foretinib is a multi-target tyrosine kinaseinhibitor with s of 04 nM and 09 nM forIC50
and Met KDR
Purity 9959Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Fruquintinib (HMPL-013) Cat No HY-19912
Fruquintinib (HMPL-013) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
33 035 and 35 nM respectively
Purity 9994Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Gandotinib (LY2784544) Cat No HY-13034
Gandotinib (LY2784544) is a potent inhibitorJAK2with of 3 nM Gandotinib (LY2784544) alsoIC50
inhibits FLT3 FLT4 FGFR2 TYK2 and TRKB withIC of 4 25 32 44 and 95 nM50
Purity 9982Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Golvatinib (E-7050) Cat No HY-13068
Golvatinib (E-7050) is a potent dual inhibitor ofboth and kinases with s of 14c-Met VEGFR2 IC50
and 16 nM respectively
Purity 9989Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
GW768505A free baseCat No HY-125741
GW768505A free base is a potent dual inhibitor of and with a p of 781 forVEGFR2 (KDR) Tie-2 IC50
VEGFR2 GW768505A free base has anti-angiogenicactivity
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
GW806742XCat No HY-112292
GW806742X an ATP mimetic and a potent MLKL(Mixed Lineage Kinase Domain-Like protein)inhibitor binds the MLKL pseudokinase domain witha of 93 μM GW806742X has activity againstKd
( =2 nM) GW806742X retards MLKLVEGFR2 IC50
membrane translocation and inhibits necroptosis
Purity 9991Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
GW806742X hydrochlorideCat No HY-112292A
GW806742X hydrochloride an ATP mimetic and apotent MLKL (Mixed Lineage Kinase Domain-Like
inhibitor binds the MLKL pseudokinaseprotein)domain with a of 93 μM GW806742XKd
hydrochloride has activity against ( =2VEGFR2 IC50
nM)
Purity 9877Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
hVEGF-IN-1Cat No HY-101931
hVEGF-IN-1 a quinazoline derivative couldspecifically bind to the G-rich sequence in theinternal ribosome entry site A (IRES-A) anddestabilize the G-quadruplex structure hVEGF-IN-1binds to the IRES-A (WT) with a of 0928 μMKd
in SPR experiments
Purity 9831Clinical Data No Development ReportedSize 1 mg 5 mg 10 mg
HypothemycinCat No HY-107417
Hypothemycin a fungal polyketide is amultikinase inhibitor with s of 1070 nM 1738Ki
nM 90 nM 900 nM15 μM and 8424 μM for VEGFR2VEGFR1 MEK1MEK2 FLT-3 and respectivelyPDGFRβPDGFRα ERK1ERK2
Purity ge980Clinical Data No Development ReportedSize 1 mg
Ilorasertib (ABT-348) Cat No HY-16018
Ilorasertib (ABT-348) is a potent andATP-competitive multitargeted kinase inhibitorwhich inhibits and Aurora C Aurora B Aurora
with s of 1 nM 7 nM 120 nM respectivelyA IC50
Purity ge980Clinical Data Phase 2Size 50 mg 100 mg
6 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A
Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50
respectively
Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
JI-101Cat No HY-16265
JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity
Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
JNJ-38158471Cat No HY-18317
JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50
and with s of 180 and 500 nMRet Kit IC50
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
K00546Cat No HY-103647
K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B
respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50
respectively
Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Ki20227Cat No HY-10408
Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)
s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50
(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit
(platelet-derived growth factorhellipPDGFRβ
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
Ki8751Cat No HY-12038
Ki8751 is a potent inhibitor with an VEGFR2 IC50
of 09 nM
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
KRN-633Cat No HY-12060
KRN-633 is a potent inhibitor with s ofVEGFR IC50
170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively
Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib (E7080) Cat No HY-10981
Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3
and shows potentFGFR1-4 PDGFR KIT RETantitumor activities
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A
Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT
shows potent antitumor activitiesRET
Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Linifanib (ABT-869 AL-39324) Cat No HY-50751
Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50
PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity
Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 7
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Ilorasertib hydrochloride (ABT-348 hydrochloride) Cat No HY-16018A
Ilorasertib (ABT-348 hydrochloride) is a potentand ATP-competitive multitargeted kinaseinhibitor which inhibits Aurora C Aurora Band with s of 1 nM 7 nM 120 nMAurora A IC50
respectively
Purity 9891Clinical Data Phase 2Size 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
JI-101Cat No HY-16265
JI-101 is an orally available multi-kinaseinhibitor of and withVEGFR2 PDGFRβ EphB4potent anti-cancer activity
Purity 9943Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
JNJ-38158471Cat No HY-18317
JNJ-38158471 is a well tolerated orallyavailable highly selective inhibitorVEGFR-2with an of 40 nM JNJ-38158471 also inhibitsIC50
and with s of 180 and 500 nMRet Kit IC50
respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
K00546Cat No HY-103647
K00546 is a potent and inhibitor withCDK1 CDK2s of 06 nM and 05 nM for andIC50 CDK1cyclin B
respectively K00546 is also aCDK2cyclin Apotent and CDC2-like kinase 1 (CLK1) CLK3inhibitor with s of 89 nM and 292 nMIC50
respectively
Purity 9878Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Ki20227Cat No HY-10408
Ki20227 is an orally active and highly selective inhibitor withc-Fms tyrosine kinase (CSF1R)
s of 2 nM 12 nM 451 and 217 nM for CSF1RIC50
(vascular endothelial growth factorVEGFR2receptor-2) (stem cell factor receptor) andc-Kit
(platelet-derived growth factorhellipPDGFRβ
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
Ki8751Cat No HY-12038
Ki8751 is a potent inhibitor with an VEGFR2 IC50
of 09 nM
Purity 9917Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
KRN-633Cat No HY-12060
KRN-633 is a potent inhibitor with s ofVEGFR IC50
170 160 and 125 nM for VEGFR1 VEGFR2 and VEGFR3respectively
Purity 9937Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib (E7080) Cat No HY-10981
Lenvatinib (E7080) is an oral multi-targetedtyrosine kinase inhibitor that inhibits VEGFR1-3
and shows potentFGFR1-4 PDGFR KIT RETantitumor activities
Purity 9987Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Lenvatinib mesylate (E7080 mesylate) Cat No HY-10981A
Lenvatinib mesylate (E7080 mesylate) an oralmulti-targeted tyrosine kinase inhibitor thatinhibits andVEGFR1-3 FGFR1-4 PDGFR KIT
shows potent antitumor activitiesRET
Purity 9986Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Linifanib (ABT-869 AL-39324) Cat No HY-50751
Linifanib (ABT-869) is a potent and orally activemulti-target inhibitor of and familyVEGFR PDGFRwith s of 4 3 66 and 4 nM for KDR FLT1IC50
PDGFRβ and FLT3 respectively Linifanib showsprominent antitumor activity
Purity 9972Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 7
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Lucitanib (E-3810) Cat No HY-15391
Lucitanib (E-3810) is a novel dual inhibitor of and potently and selectivelyVEGFR FGFR
inhibits andVEGFR1 VEGFR2 VEGFR3 FGFR1 with s of 7 nM 25 nM 10 nM 175 nMFGFR2 IC50
and 825 nM respectively
Purity 9932Clinical Data Phase 3Size 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
MAZ51Cat No HY-116624
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4)tyrosine kinase MAZ51 inhibits VEGF-C-inducedactivation of VEGFR-3 without blockingVEGF-C-mediated stimulation of VEGFR2 MAZ51 hadno effect on ligand-induced autophosphorylation ofEGFR IGF-1R and PDGFRβ
Purity 9821Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg
MGCD-265 analogCat No HY-10991
MGCD-265 analog is a potent and oral activeinhibitor of and tyrosinec-Met VEGFR2kinases with s of 29 nM and 10 nMIC50
respectively MGCD-265 analog has significantantitumor activity
Purity 9857Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
ML786 dihydrochlorideCat No HY-14979A
ML786 dihydrochloride is a potent and orallybioavailable inhibitor with s of 21Raf IC50
42 and 25 nM for ΔB-RafV600E wt B-Rafand respectively ML786 dihydrochlorideC-Rafalso inhibits and Abl-1 DDR2 EPHA2 KDR RET( =lt05 70 11 62 08 nM)IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Motesanib (AMG 706) Cat No HY-10228
Motesanib (AMG 706) is a potent ATP-competitiveinhibitor of with VEGFR123 IC lt50
bgts of 2 nM3 nM6 nM respectively and hassimilar activity against Kit and is appr 10-fold
more selective for VEGFR than PDGFR and Ret
Purity 9999Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Motesanib Diphosphate (AMG 706 Diphosphate) Cat No HY-10229
Motesanib Diphosphate (AMG 706 Diphosphate) is apotent ATP-competitive inhibitor of VEGFR123with s of 2 nM3 nM6 nM respectively andIC50
has similar activity against Kit and isapproximately 10-fold more selective for VEGFRthan PDGFR and Ret
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
NingetinibCat No HY-107145A
Ningetinib is a potent orally bioavailable smallmolecule tyrosine kinase inhibitor ( ) with sTKI IC50
of 67 19 and lt10 nM for c-Met VEGFR2and respectivelyAxl
Purity 9979Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Ningetinib TosylateCat No HY-107145
Ningetinib Tosylate is a potent orallybioavailable small molecule tyrosine kinaseinhibitor ( ) with s of 67 19 and lt10TKI IC50
nM for and respectivelyc-Met VEGFR2 Axl
Purity 9992Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Nintedanib (BIBF 1120) Cat No HY-50904
Nintedanib (BIBF 1120) is a potent tripleangiokinase inhibitor for VEGFR123 FGFR123and with s of 34 nM13 nM13 nM 69PDGFRαβ IC50
nM37 nM108 nM and 59 nM65 nM respectively
Purity 9997Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg 1 g
Nintedanib esylate (BIBF 1120 esylate) Cat No HY-11106
Nintedanib esylate (BIBF 1120 esylate) is a potenttriple angiokinase inhibitor for VEGFR123
and with s of 34 nM13FGFR123 PDGFRαβ IC50
nM13 nM 69 nM37 nM108 nM and 59 nM65 nMrespectively
Purity 9993Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
8 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
NVP-ACC789 (ACC-789 ZK202650) Cat No HY-19624
NVP-ACC789 is an inhibitor of human VEGFR-1 (mouse ) and VEGFR-2 VEGFR-2 VEGFR-3 PDGFR-β
with s of 038 002 (023) 018 14 μMIC50
respectively
Purity 9994Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
NVP-BAW2881 (BAW2881) Cat No HY-100394
NVP-BAW2881 (BAW2881) is a potent and selective inhibitor with an of 4 nMVEGFR2 IC50
Purity 9842Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg
ODM-203Cat No HY-119367
ODM-203 is a potent and familiesFGFR VEGFRinhibitor with s of 11 16 6 35 nM towardsIC50
recombinant FGFR1 FGFR2 FGFR3 and FGFR4 as wellas 26 9 5 nM towards VEGFR1 VEGFR2 and VEGFR3respectively ODM-203 exhibits strong anti-tumoractivity and induces anti-tumor immunity
Purity 9933Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
Oglufanide (H-Glu-Trp-OH L-Glutamyl-L-tryptophan) Cat No HY-13718
Oglufanide (H-Glu-Trp-OH) is a dipeptideimmunomodulator isolated from calf thymusOglufanide inhibits vascular endothelial growth
Oglufanide can stimulate thefactor (VEGF)immune response to andhepatitic C virus (HCV)intracellular bacterial infections
Purity 9927Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Orantinib (SU6668 TSU-68) Cat No HY-10517
Orantinib (SU6668 TSU-68) is a multi-targetedreceptor tyrosine kinase inhibitor with s of 21Ki
μM 8 nM and 12 μM for and Flt-1 PDGFRβ FGFR1respectively
Purity 9880Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
OSI-930Cat No HY-10204
OSI-930 is an orally selective inhibitor of Kit and with s of 80 nM 9KDR CSF-1R (c-Fms) IC50
nM and 15 nM respectively OSI-930 alsomoderately inhibits and lowFlt-1 c-Raf Lckactivity against and OSI-930PDGFRαβ Flt-3 Ablhas antitumor activity
Purity 9813Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Pamufetinib (TAS-115) Cat No HY-12423
TAS-115 is a potent and hepatocyte growthVEGFRfactor receptor ( )-targeted kinasec-MetHGFRinhibitor with s of 30 and 32 nM for rVEGFR2IC50
and rMET respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Pazopanib (GW786034) Cat No HY-10208
Pazopanib (GW786034) is a novel multi-targetinhibitor of VEGFR1 VEGFR2 VEGFR3 PDGFRβ
and with s of 10 30c-Kit FGFR1 c-Fms IC50
47 84 74 140 and 146 nM respectively
Purity 9977Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
Pazopanib Hydrochloride (GW786034 (Hydrochloride)) Cat No HY-12009
Pazopanib Hydrochloride (GW786034 Hydrochloride)is a novel multi-target inhibitor of VEGFR1
andVEGFR2 VEGFR3 PDGFRβ c-Kit FGFR1 with an of 10 30 47 84 74 140c-Fms IC50
and 146 nM respectively
Purity 9984Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg 500 mg
PD173074Cat No HY-10321
PD173074 is a potent inhibitor with an FGFR1 IC50
of 25 nM and also inhibits with an ofVEGFR2 IC50
100-200 nM showing 1000-fold selectivity forFGFR1 over PDGFR and c-Src
Purity 9970Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg 200 mg
wwwMedChemExpresscom 9
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Pentagamavunon-1 (PGV-1) Cat No HY-136477
Pentagamavunon-1 (PGV-1) a Curcumin analog withoral activity targets on several molecularmechanisms to induce including inhibitionapoptosisof angiogenic factors cyclooxygenase-2 ( )COX-2and vascular endothelial growth factor ( )VEGFPGV-1 inhibits activationNF-κB
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PF 477736 (PF 00477736) Cat No HY-10032
PF 477736 (PF 00477736) is a potent selective andATP-competitive inhibitor of with a ofChk1 Ki
049 nM it is also a inhibitor with a Chk2 Ki
of 47 nM
Purity 9921Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
PF-03814735Cat No HY-14574
PF-03814735 is a potent orally availableATP-competitive and reversible andaurora A
inhibitor with s of 08 and 05 nMaurora B IC50
respectively
Purity 9982Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg
Ponatinib (AP24534) Cat No HY-12047
Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity 9938Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ponatinib D8 (AP24534 D8) Cat No HY-12047S
Ponatinib D8 (AP24534 D8) is a deuterium labeledPonatinib Ponatinib (AP24534) is an orally activemulti-targeted kinase inhibitor with s of 037IC50
nM 11 nM 15 nM 22 nM and 54 nM for Abl and respectivelyPDGFRα VEGFR2 FGFR1 Src
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
PP121Cat No HY-10372
PP121 is a multi-targeted kinase inhibitor withs of 10 60 12 14 2 nM for IC50 mTOR
respectivelyDNK-PK VEGFR2 Src PDGFR
Purity 9908Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
PTC299Cat No HY-124593
PTC299 is an orally active inhibitor of VEGFA that selectively inhibits VEGFmRNA translation
protein synthesis at the post-transcriptionallevel PTC299 is also a potent inhibitor of
dihydroorotate dehydrogenase (DHODH)
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
Pz-1Cat No HY-U00437
Pz-1 is a potent and inhibitor withRET VEGFR2s of less than 1 nM for both wild typeIC50
kinases
Purity ge990Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg
R1530Cat No HY-13737
R1530 is a highly potent orally activedual-acting inhibitormitosisangiogenesiswith anti-tumor and anti-angiogenic activitiesR1530 is a multikinase inhibitor which binds to 31kinases with s of lt500 nMKd
Purity 9906Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
R916562Cat No HY-104075
R916562 is an orally active and selective inhibitor with s of 136 nM and 24AxlVEGF-R2 IC50
nM respectively R916562 has anti-angiogenesisand anti-metastasis
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
10 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
RAF265 (CHIR-265) Cat No HY-10248
RAF265 is a potent inhibitorRAF VEGFR2
Purity 9998Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg
RamucirumabCat No HY-P9920
Ramucirumab is a human antagonist for theVEGFR-2treatment of solid tumors Ramucirumab is arecombinant human immunoglobulin G1 monoclonalantibody that binds to the extracellular bindingdomain of VEGFR-2 and prevents the binding ofVEGFR ligands VEGF-A VEGF-C and VEGF-D
Purity 9940Clinical Data LaunchedSize 1 mg 5 mg 25 mg 50 mg
Ranibizumab (RG-6321) Cat No HY-P9951
Ranibizumab (RG-6321) is a humanized anti-VEGFmonoclonal antibody fragment and can recognize allVEGF-A isoforms (VEGF110 VEGF121 andVEGF165) Ranibizumab slows vision loss andin vivois used for wet age-related macular degeneration(AMD) research
Purity 9860Clinical Data LaunchedSize 1 mg
Regorafenib (BAY 73-4506) Cat No HY-10331
Regorafenib (BAY 73-4506) is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
134246 22 7 15 and 25 nM for VEGFR123 and respectivelyPDGFRβ Kit RET Raf-1
Purity 9965Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib D3 (BAY 73-4506 D3) Cat No HY-10331S
Regorafenib D3 (BAY 73-4506 D3) is a deuteriumlabeled Regorafenib Regorafenib is amulti-targeted receptor tyrosine kinase inhibitor
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) Cat No HY-13308
Regorafenib Hydrochloride (BAY 73-4506hydrochloride) is a multi-target inhibitor for
and withVEGFR123 PDGFRβ Kit RET Raf-1s of 134246 22 7 15 and 25 nMIC50
respectively
Purity 9958Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Regorafenib monohydrate (BAY 73-4506 monohydrate) Cat No HY-10331A
Regorafenib monohydrate (BAY 73-4506 monohydrate)is a multi-target inhibitor for VEGFR123
and with s ofPDGFRβ Kit RET Raf-1 IC50
134246 22 7 15 and 25 nM respectively
Purity 9996Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 50 mg 100 mg
Ripretinib (DCC-2618) Cat No HY-112306
Ripretinib (DCC-2618) is an orally bioavailableselective and switch-control inhibitorKIT PDGFRA
Purity 9890Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SAR131675Cat No HY-15458
SAR131675 is a potent and selective VEGFR3inhibitor with an of 23 nMIC50
Purity 9948Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg
SCR-1481B1 (c-Met inhibitor 2) Cat No HY-18711A
SCR-1481B1 (c-Met inhibitor 2) is a potentcompound that has activity against cancersdependent upon Met activation and also hasactivity against cancers as a VEGFR inhibitor
Purity 9999Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
wwwMedChemExpresscom 11
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Semaxinib (SU5416) Cat No HY-10374
Semaxinib (SU5416) is a potent and selectiveinhibitor of ( ) with an ofVEGFR Flk-1KDR IC50
123 μM
Purity 9996Clinical Data Phase 2Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Sitravatinib (MGCD516 MG-516) Cat No HY-16961
Sitravatinib (MGCD516) is an orally bioavailable inhibitor withreceptor tyrosine kinase (RTK)
s of 15 nM 2 nM 2 nM 5 nM 6 nM 6 nM 8IC50
nM 05 nM 29 nM 5 nM and 9 nM for Axl MERVEGFR3 VEGFR2 VEGFR1 KIT FLT3 DDR2 DDR1TRKA TRKB respectively
Purity 9985Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Sitravatinib malate (MGCD516 malate MG-516 malate) Cat No HY-16961A
Sitravatinib malate (MGCD516 malate) is an orallybioavailable receptor tyrosine kinase (RTK)inhibitor with s of 15 nM 2 nM 2 nM 5 nMIC50
6 nM 6 nM 8 nM 05 nM 29 nM 5 nM and 9 nMfor Axl MER VEGFR3 VEGFR2 VEGFR1 KIT FLT3DDR2 DDR1 TRKA TRKB respectively
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Sorafenib (Bay 43-9006) Cat No HY-10201
Sorafenib (Bay 43-9006) is a potent and orallyactive inhibitor with s of 6 nM and 20 nMRaf IC50
for and respectively Sorafenib isRaf-1 B-Rafa multikinase inhibitor with s of 90 nM 15IC50
nM 20 nM 57 nM and 58 nM for VEGFR2 VEGFR3 and respectivelyPDGFRβ FLT3 c-Kit
Purity 9992Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
Sorafenib (D3) (Bay 43-9006 (D3) Donafenib) Cat No HY-10201S
Sorafenib (D3) (Bay 43-9006 (D3)) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity 9957Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
Sorafenib (D4) (Bay 43-9006 (D4)) Cat No HY-10201S1
Sorafenib D4 (Bay 43-9006 D4) is the deuteriumlabeled Sorafenib Sorafenib is a multikinaseinhibitor IC s of 6 nM 20 nM and 22 nM for50
Raf-1 B-Raf and VEGFR-3 respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Sorafenib Tosylate (Bay 43-9006 Tosylate) Cat No HY-10201A
Sorafenib Tosylate (Bay 43-9006 Tosylate) is apotent and orally active inhibitor with sRaf IC50
of 6 nM and 20 nM for and Raf-1 B-Rafrespectively
Purity 9975Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 500 mg
SU 5402Cat No HY-10407
SU 5402 is a potent multi-targeted receptortyrosine kinase inhibitor with of 20 nM 30IC50
nM and 510 nM for and VEGFR2 FGFR1 PDGFRβrespectively
Purity 9939Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
SU14813Cat No HY-10501
SU14813 is a multi-targeted receptor tyrosinekinases inhibitor with s of 50 2 4 15 nMIC50
for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9890Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
SU14813 maleateCat No HY-10501A
SU14813 maleate is a multi-targeted receptortyrosine kinases inhibitor with s of 50 2 4IC50
15 nM for and VEGFR2 VEGFR1 PDGFRβ KIT
Purity 9995Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg
12 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
SU1498 (AG 1498 Tyrphostin SU 1498) Cat No HY-19326
SU1498 (AG 1498) is a selective inhibitor of the inhibits with an of value ofVEGFR2 Flk-1 IC50
700 nM
Purity 9837Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg
SU4312Cat No HY-100349
SU4312 is the racemate of (Z)-SU4312 and(E)-SU4312 (Z)-SU4312 inhibits PDGFR and FLK-1with s of 194 and 08 μM respectivelyIC50
(E)-SU4312 inhibits PDGFR FLK-1 EGFR HER-2 andIGF-1R with s of 242 52 185 169 andIC50
100 μM respectively
Purity 9819Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
SU5204Cat No HY-126319
SU5204 a tyrosine kinase inhibitor has s ofIC50
4 and 515 μM for and FLK-1 (VEGFR-2) HER2respectively
Purity 9889Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
SU5205Cat No HY-21289
SU5205 is an inhibitor of withVEGFR2 (FLK-1)an of 96 μMIC50
Purity 9844Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg
SU5208Cat No HY-136209
SU5208 inhibits vascular endothelial growth factorreceptor-2 (VEGFR2)
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
SU5214 (SU4949) Cat No HY-21292
SU5214 is a potent inhibitor extractedVEGFR2from patent US5834504A SU5214 has s of 148IC50
microM ( ) and 367 microM ( ) respectivelyFLK-1 EGFR
Purity 9829Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 25 mg 50 mg 100 mg
SU5408 (VEGFR2 Kinase Inhibitor I) Cat No HY-103002
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent andcell-permeable inhibitor of kinase with anVEGFR2
of 70 nMIC50
Purity ge980Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg
Sulfatinib (HMPL-012) Cat No HY-12297
Sulfatinib (HMPL-012) is a potent and highlyselective tyrosine kinase inhibitor against
and with s of in aVEGFR123 FGFR1 CSF1R IC50
range of 1 to 24 nM
Purity 9801Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg 100 mg
Sunitinib (SU 11248) Cat No HY-10255A
Sunitinib (SU 11248) is a multi-targeted receptortyrosine kinase inhibitor with s of 80 nM andIC50
2 nM for and respectivelyVEGFR2 PDGFRβ
Purity 9896Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib D10 (SU 11248 D10) Cat No HY-10255AS
Sunitinib D10 (SU 11248 D10) is a deuteriumlabeled Sunitinib Sunitinib is a multi-targetedreceptor tyrosine kinase inhibitor with s ofIC50
80 nM and 2 nM for and VEGFR2 PDGFRβrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
wwwMedChemExpresscom 13
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Sunitinib Malate (SU 11248 Malate) Cat No HY-10255
Sunitinib Malate (SU 11248 Malate) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity 9947Clinical Data LaunchedSize 10 mM times 1 mL 100 mg 200 mg 500 mg
Sunitinib-d4Cat No HY-10255AS1
Sunitinib-d4 (SU 11248-d4) is the deuteriumlabeled Sunitinib Sunitinib (SU 11248) is amulti-targeted receptor tyrosine kinase inhibitorwith s of 80 nM and 2 nM for andIC50 VEGFR2
respectivelyPDGFRβ
Purity gt98Clinical DataSize 25 mg 1 mg 25 mg
TAK-593Cat No HY-15506
TAK-593 is a potent and familyVEGFR PDGFRinhibitor with s of 32 095 11 43 and 13IC50
nM for VEGFR1 VEGFR2 VEGFR3 PDFGRα and PDFGRβrespectively
Purity 9962Clinical Data Phase 1Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Tanshinone IIA (Dan Shen ketone) Cat No HY-N0135
Tanshinone IIA (Tan IIA) is one of the maincompositions in the root of red-rooted salviaTanshinone IIA may suppress angiogenesis bytargeting the protein kinase domains of
VEGF VEGFR2
Purity 9937Clinical Data Phase 4Size 10 mg 25 mg 50 mg
TAS-115 mesylate (TAS-115 methanesulfonate) Cat No HY-12423A
TAS-115 mesylate is a potent and hepatocyteVEGFRgrowth factor receptor ( )-targetedc-MetHGFRkinase inhibitor with s of 30 and 32 nM forIC50
rVEGFR2 and rMET respectively
Purity 9915Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib (Bay 57-9352) Cat No HY-10527
Telatinib (Bay 57-9352) is an orally active smallmolecule inhibitor of VEGFR2 VEGFR3 PDGFαand with s of 6 4 15 and 1 nMc-Kit IC50
respectively
Purity 9872Clinical Data Phase 2Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Telatinib mesylate (Bay 57-9352 mesylate) Cat No HY-10527C
Telatinib mesylate (Bay 57-9352 mesylate) is apotent and orally active VEGFR2 VEGFR3 PDGFαand inhibitor with s of 6 nM 4 nM 15 nMc-Kit IC50
and 1 nM respectively
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
Tesevatinib (XL-647 EXEL-7647 KD-019) Cat No HY-13314
Tesevatinib (XL-647 EXEL-7647 KD-019) is anorally available multi-target tyrosine kinaseinhibitor inhibits andEGFR ErbB2 KDR Flt4
kinase with s of 03 16 15 87 andEphB4 IC50
14 nM
Purity 9921Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg
TG 100572Cat No HY-10184
TG 100572 is a multi-targeted kinase inhibitorwhich inhibits and receptor tyrosine kinases Src
has s of 2 7 2 16 13 5 05 6kinases IC50
01 04 1 02 nM for VEGFR1 VEGFR2 FGFR1FGFR2 PDGFRβ Fgr Fyn Hck Lck Lyn Src Yesrespectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
TG 100572 HydrochlorideCat No HY-10185
TG 100572 Hydrochloride is a multi-targeted kinaseinhibitor which inhibits receptor tyrosine kinasesand has s of 2 7 2 16 13 5Src kinases IC50
05 6 01 04 1 02 nM for VEGFR1 VEGFR2FGFR1 FGFR2 PDGFRβ Fgr Fyn Hck Lck LynSrc Yes respectively
Purity 9958Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 50 mg
14 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
TG 100801Cat No HY-10186
TG 100801 is a prodrug that generates TG 100572 byde-esterification in development to treatage-related macular degeneration
Purity 9860Clinical Data Phase 2Size 5 mg 10 mg 50 mg
TG 100801 HydrochlorideCat No HY-10187
TG 100801 Hydrochloride is a prodrug thatgenerates TG 100572 by de-esterification indevelopment to treat age-related maculardegeneration
Purity gt98Clinical Data Phase 2Size 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-1Cat No HY-112294
TIE-2VEGFR-2 kinase-IN-1 is used for thesynthesis of TIE-2 andor VEGFR-2 inhibitorsextracted from patent WO2003022852 example 14TIE-2VEGFR-2 kinase-IN-1 is used for the study ofdiseases associated with inappropriateangiogenesis
Purity 9991Clinical Data No Development ReportedSize 1 mg 5 mg
TIE-2VEGFR-2 kinase-IN-2Cat No HY-12572
TIE-2VEGFR-2 kinase-IN-2 is a potent dual VEGFR2and inhibitor with values of 861 andTie-2 pIC50
856 respectively TIE-2VEGFR-2 kinase-IN-2 isan anti-angiogenic agent and can be used forcancer research
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Tivozanib (AV-951 KRN951) Cat No HY-10977
Tivozanib (AV-951 KRN951) is a highly potent andselective inhibitor with s ofVEGFR 123 IC50
021 016 and 024 nM in cell assayrespectively
Purity 9927Clinical Data LaunchedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg 200 mg
Toceranib (SU11654 PHA 291639E) Cat No HY-10330
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9625Clinical Data LaunchedSize 10 mg 50 mg
Toceranib phosphate (SU11654 phosphate PHA 291639E phosphate) Cat No HY-10330A
Toceranib phosphate (SU11654 phosphate) is anorally active receptor tyrosine kinase (RTK)inhibitor and it potently inhibits PDGFR
and with s of 5 and 6 nM for PDGFRβVEGFR Kit Ki
and Flk-1KDR respectively
Purity 9802Clinical Data LaunchedSize 10 mg 50 mg
Toceranib-d8Cat No HY-10330S
Toceranib-d8 (SU11654-d8) is the deuterium labeledToceranib Toceranib (SU11654) is an orally activereceptor tyrosine kinase (RTK) inhibitor and itpotently inhibits and with sPDGFR VEGFR Kit Ki
of 5 and 6 nM for PDGFRβ and Flk-1KDRrespectively
Purity gt98Clinical DataSize 1 mg 10 mg
Tyrosine kinase-IN-1Cat No HY-100315
Tyrosine kinase-IN-1 is a multi-targeted tyrosinekinase inhibitor with s of 4 20 4 2 nM forIC50
and respectivelyKDR Flt-1 FGFR1 PDGFRα
Purity 9947Clinical Data No Development ReportedSize 10 mM times 1 mL 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg
Tyrphostin A9 (Tyrphostin 9 Malonoben) Cat No HY-15511
Tyrphostin A9 a inhibitor is a potentPDGFRinducer of mitochondrial fission Tyrphostin A9emerged as the most potent and selective of 51tyrosine kinase inhibitors tested against theTNF-induced respiratory burst Tyrphostin A9 has
activitiesanti-influenza virus
Purity 9987Clinical Data No Development ReportedSize 10 mM times 1 mL 50 mg 100 mg 500 mg
wwwMedChemExpresscom 15
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
Tyrphostin AG1433 (SU1433 AG1433) Cat No HY-119757
Tyrphostin AG1433 (SU1433) is a tyrosine kinasesinhibitor AG1433 is also a selective andPDGFRβ
inhibitor with s of 50 μMVEGFR-2 (Flk-1KDR) IC50
and 93 μM respectively Tyrphostin AG1433prevents blood vessel formation
Purity 9920Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
Vandetanib (ZD6474) Cat No HY-10260
Vandetanib (D6474) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM) Vandetanib also has activity versusIC50
the tyrosine kinase activity of VEGFR3FLT4( =110 nM) and ( =500 nM)IC50 EGFRHER1 IC50
Purity 9989Clinical Data LaunchedSize 10 mM times 1 mL 10 mg 25 mg 50 mg 100 mg 500 mg
Vandetanib hydrochloride (ZD6474 hydrochloride) Cat No HY-10260B
Vandetanib hydrochloride (D6474 hydrochloride) isa potent orally active inhibitor of VEGFR2KDRtyrosine kinase activity ( =40 nM) VandetanibIC50
hydrochloride also has activity versus thetyrosine kinase activity of ( =110VEGFR3FLT4 IC50
nM) and ( =500 nM)EGFRHER1 IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib trifluoroacetate (ZD6474 trifluoroacetate) Cat No HY-10260A
Vandetanib trifluoroacetate (D6474trifluoroacetate) is a potent orally activeinhibitor of tyrosine kinase activityVEGFR2KDR( =40 nM)IC50
Purity gt98Clinical Data LaunchedSize 1 mg 5 mg
Vandetanib-d4Cat No HY-10260S1
Vandetanib-d4 (ZD6474-d4) is the deuterium labeledVandetanib Vandetanib (ZD6474) is a potentorally active inhibitor of tyrosineVEGFR2KDRkinase activity ( =40 nM)IC50
Purity gt98Clinical DataSize 25 mg 1 mg 5 mg 10 mg
Vatalanib dihydrochloride (PTK787 dihydrochloride CGP-797870
dihydrochloride ZK-222584 dihydrochloride) Cat No HY-12018
Vatalanib dihydrochloride (PTK787 dihydrochloride)is an inhibitor of with of 37 nMVEGFR2KDR IC50
Purity 9997Clinical Data Phase 3Size 10 mM times 1 mL 10 mg 50 mg 100 mg
Vatalanib free base (PTK787 free base PTKZK free base
CGP-79787 free base ZK-222584 free base) Cat No HY-10203
Vatalanib (PTK787 ZK-222584 CGP-79787) is aninhibitor of with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical Data Phase 3Size 1 mg 5 mg
Vatalanib-d4 dihydrochlorideCat No HY-12018S
Vatalanib-d4 (PTK787-d4) dihydrochloride is thedeuterium labeled Vatalanib dihydrochlorideVatalanib (PTK787) dihydrochloride is an inhibitorof with of 37 nMVEGFR2KDR IC50
Purity gt98Clinical DataSize 1 mg 10 mg
VEGFR-2-IN-5Cat No HY-18625
VEGFR-2-IN-5 is a inhibitor extracted fromVEGFR2patent WO2013055780A1 Page 69
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg 100 mg
VEGFR-2-IN-5 hydrochlorideCat No HY-18625A
VEGFR-2-IN-5 hydrochloride is a inhibitorVEGFR2extracted from patent WO2013055780A1 Page 69
Purity 9974Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
16 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
VEGFR-2-IN-6Cat No HY-131658
VEGFR-2-IN-6 (example 64) is a inhibitorVEGFR2(angiogenesis modulator) which is extracted frompatent WO 02059110
Purity gt98Clinical Data No Development ReportedSize 5 mg 10 mg 25 mg 50 mg 100 mg
VEGFR-2-IN-9 (KDR-in-4) Cat No HY-101628
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insertdomain-containing receptor ( ) inhibitorKDRVEGFR2with an of 7 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
VEGFR-3-IN-1Cat No HY-132305
VEGFR-3-IN-1 is a potent and selective VEGFR3inhibitor with an of 1104 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
Vorolanib (CM082 X-82) Cat No HY-109019
Vorolanib (CM082) is an orally active potentmultikinase inhibitor Vorolanib is aVEGFRPDGFRpotent ATP-binding cassette (ABC) transporterinhibitor Vorolanib is an angiogenesis inhibitorand has antitumor activity combined with ZD1839(HY-50895)
Purity 9980Clinical Data Phase 3Size 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
WHI-P180 (Janex 3) Cat No HY-15769
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity 9976Clinical Data No Development ReportedSize 10 mM times 1 mL 2 mg 5 mg 10 mg 50 mg
WHI-P180 hydrochloride (Janex 3 hydrochloride ) Cat No HY-15769A
WHI-P180 (Janex 3) is a multi-kinase inhibitorinhibits and with s of 5 nMRET KDR EGFR IC50
66 nM and 4 μM respectively
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
XanthatinCat No HY-N3032
Xanthatin is isolated from Xanthium leavesstrumarium
Purity 9979Clinical Data No Development ReportedSize 10 mM times 1 mL 5 mg 10 mg 50 mg 100 mg
ZD-4190Cat No HY-U00002
ZD-4190 is a potent orally available inhibitor ofthe vascular endothelial cell growth factorreceptor 2 ( ) and of epidermal growthVEGFR2factor receptor ( ) signalling used for theEGFRtreatment of cancer
Purity 9920Clinical Data No Development ReportedSize 5 mg 10 mg 50 mg
ZK-261991Cat No HY-15333
ZK-261991 is an orally active tyrosineVEGFRkinase inhibitor with an of 5 nM for VEGFR2IC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM 306416 (CB 676475) Cat No HY-13785
ZM-306416 (CB 676475) is a potent inhibitor of with s of 01 and 2 μM for KDR and FltVEGFR IC50
respectively ZM-306416 is also a inhibitorEGFRwith an of lt10 nMIC50
Purity 9980Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
wwwMedChemExpresscom 17
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom
ZM323881Cat No HY-15467
ZM323881 is a potent and selective VEGFR2inhibitor with an of less than 2 nMIC50
Purity gt98Clinical Data No Development ReportedSize 1 mg 5 mg
ZM323881 hydrochlorideCat No HY-15467A
ZM323881 hydrochloride is a potent and selective inhibitor with an of less than 2 nMVEGFR2 IC50
Purity 9860Clinical Data No Development ReportedSize 10 mM times 1 mL 10 mg 50 mg
18 Tel 609-228-6898 Fax 609-228-5909 Email salesMedChemExpresscom